Philip Gribbon, Head of Discovery Research at the Fraunhofern institute of Translational Medicine and Pharmacology, discusses his work on small molecule screening and collaborative drug discovery efforts. Plus, Gribbon explores the use of induced pluripotent stem cells (iPSCs) for translational relevance, highlights a shift towards patient-derived assays, and discusses PROTACs, an exciting new drug modality. These approaches hold promise for enhancing drug discovery and development.